Physician profile
William A Simpson
NPI 1437574134
$29,180.94
in general payments reported to CMS, 2019-2025
28 companies · $1,235 in 2025
The $1,235 reported for 2025 was more than what 90% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $24K · 2022: $846 · 2023: $1,916 · 2024: $847 · 2025: $1,235.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,262 · Travel and Lodging: $737.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,261.77 |
| Travel and Lodging | $736.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $24,068.78 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,028.62 | 2021-2025 | Breztri, Airsupra, Farxiga |
| Allergan, INC. | $825.00 | 2021 | |
| Intuitive Surgical, INC. | $736.96 | 2023 | Da Vinci Surgical System |
| Sanofi-Aventis U.S. LLC | $317.64 | 2021-2022 | |
| Novo Nordisk INC | $304.15 | 2022-2025 | Ozempic, Rybelsus |
| Lilly USA, LLC | $279.06 | 2023-2025 | Mounjaro, Jardiance, Zepbound |
| Pfizer INC. | $218.93 | 2023-2025 | |
| Phathom Pharmaceuticals, INC. | $171.23 | 2024-2025 | Voquezna |
| Xeris Pharmaceuticals, INC. | $166.38 | 2021-2025 | Gvoke Hypopen |
| Amgen INC. | $161.89 | 2022-2024 | Otezla, Repatha |
| Lundbeck LLC | $134.01 | 2023-2025 | Rexulti |
| Glaxosmithkline, LLC. | $110.84 | 2022-2023 | Trelegy Ellipta |
| Mylan Specialty L.P. | $96.05 | 2023-2024 | Yupelri |
| Medtronic, INC. | $64.90 | 2023-2025 | Minimed 780g, Intellis Adaptivestim |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shield Therapeutics INC | $62.83 | 2023-2024 | Accrufer |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $62.08 | 2024-2025 | Caplyta |
| Antares Pharma, INC. | $56.80 | 2025 | Xyosted |
| Otsuka America Pharmaceutical, INC. | $51.44 | 2023-2024 | Rexulti |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $50.24 | 2023-2024 | Xifaxan, Trulance |
| Axsome Therapeutics, INC. | $39.37 | 2025 | Auvelity |
| Idorsia Pharmaceuticals US INC | $33.17 | 2023 | Quviviq |
| Exact Sciences Corporation | $31.95 | 2025 | The Cologuard Plus Collection Kit |
| Insulet Corporation | $30.42 | 2021-2023 | Omnipod |
| Harmony Biosciences LLC | $28.93 | 2025 | |
| Saluda Medical Americas, INC. | $20.28 | 2025 | Evoke |
| Viatris Specialty LLC | $16.52 | 2025 | Yupelri |
| Genentech USA, INC. | $12.47 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Simpson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.